<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01517568</url>
  </required_header>
  <id_info>
    <org_study_id>NN2211-1699</org_study_id>
    <secondary_id>2006-002293-22</secondary_id>
    <nct_id>NCT01517568</nct_id>
  </id_info>
  <brief_title>Metabolism and Excretion of Liraglutide in Healthy Male Volunteers</brief_title>
  <official_title>A Single-Centre, Open Label Trial Investigating the Metabolites in Plasma, Urine and Faeces After a Single Subcutaneous Dose of [3H]-Liraglutide to Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novo Nordisk A/S</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novo Nordisk A/S</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This trial is conducted in Europe. The aim of this trial is characterise the metabolic
      profile of liraglutide in plasma, urine, and faeces after a single injection of
      [3H]-liraglutide.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2006</start_date>
  <completion_date type="Actual">December 2006</completion_date>
  <primary_completion_date type="Actual">December 2006</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Profile and identity of the major metabolites of tritium labelled liraglutide in plasma, urine, and faeces</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Total recovery of tritium, [3H]-liraglutide and metabolites in urine and faeces</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Area under the curve</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmax, maximum concentration</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>tmax, time to reach Cmax</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>t½, terminal half-life</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The distribution of [3H]-liraglutide in whole blood versus plasma</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events</measure>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">7</enrollment>
  <condition>Diabetes</condition>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Liraglutide</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>liraglutide [3H]</intervention_name>
    <description>A single dose of 0.75 mg will be given as a subcutaneous injection</description>
    <arm_group_label>Liraglutide</arm_group_label>
    <other_name>[3H]-liraglutide</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Good general health as judged by the Investigator, based on medical history, physical
             examination including 12-lead ECG (electrocardiogram), vital signs, and blood and
             urinary laboratory assessments

          -  BMI (Boday Mass Index) of 20.0-27.0 kg/m^2, both inclusive

        Exclusion Criteria:

          -  History of any clinically significant renal, hepatic, cardiovascular, pulmonary,
             gastrointestinal, metabolic, endocrine, haematological, neurological, psychiatric
             disease or other major disorders that may interfere with the objectives of the trial,
             as judged by the Investigator

          -  Impaired renal function

          -  Active hepatitis B or active hepatitis C

          -  Positive human immunodeficiency virus (HIV) antibodies

          -  Any clinically significant abnormal ECG, as judged by the Investigator

          -  Any clinically significant abnormal laboratory test results, as judged by the
             Investigator

          -  Acute infection or inflammation or other illness that may influence the metabolism and
             excretion pattern of the trial product, as judged by the Investigator

          -  Known or suspected allergy to trial product(s) or related products

          -  History of alcoholism or drug abuse or positive results in alcohol and drug screens

          -  Smoking of more than 5 cigarettes per day

          -  Habitual excessive consumption of methylxanthine-containing (theophylline, caffeine or
             theobromine) beverages and foods (coffee, tea, soft drinks such as red bull, cola,
             chocolate) as judged by the Investigator

          -  Excessive consumption of a diet deviating from a normal diet, as judged by the
             Investigator
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Global Clinical Registry (GCR, 1452)</last_name>
    <role>Study Director</role>
    <affiliation>Novo Nordisk A/S</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Groningen</city>
        <zip>9728 NZ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <link>
    <url>http://novonordisk-trials.com</url>
    <description>Clinical Trials at Novo Nordisk</description>
  </link>
  <results_reference>
    <citation>Malm-Erjefält M, Bjørnsdottir I, Vanggaard J, Helleberg H, Larsen U, Oosterhuis B, van Lier JJ, Zdravkovic M, Olsen AK. Metabolism and excretion of the once-daily human glucagon-like peptide-1 analog liraglutide in healthy male subjects and its in vitro degradation by dipeptidyl peptidase IV and neutral endopeptidase. Drug Metab Dispos. 2010 Nov;38(11):1944-53. doi: 10.1124/dmd.110.034066. Epub 2010 Aug 13.</citation>
    <PMID>20709939</PMID>
  </results_reference>
  <verification_date>January 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 21, 2012</study_first_submitted>
  <study_first_submitted_qc>January 21, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 25, 2012</study_first_posted>
  <last_update_submitted>January 25, 2017</last_update_submitted>
  <last_update_submitted_qc>January 25, 2017</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 26, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liraglutide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

